Previous 10 | Next 10 |
Stock Market Today Mid-Morning Updates On Friday, the Dow Jones Industrial Average is up by 60 points. This comes as the U.S. and European Union (EU) announced a new partnership to reduce Europe’s reliance on Russian energy, the start of a years-long effort to further iso...
DexCom (NASDAQ:DXCM) has announced 4-for-1 stock split of its common shares on Friday. It will see the company's outstanding shares increasing to 800M from current 200M shares. Record date is set to May 19, 2022 for trading to begin on a split-adjusted basis from Jun. 10, 2020....
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today that its Board of Directors has approved a four-for-one forward split (the “Stock Split”) of Dexcom’s common stock. The S...
Hurt by the underperformance of several medical device makers on Wednesday, the S&P 500 Healthcare Index has lagged all but one sector in the benchmark index. Notable decliners include, ResMed (RMD -6.8%), Edwards Lifesciences (EW -4.2%), Boston Scientific (BSX -3.7%), and Stryker Corpora...
Medical device companies can be excellent investments thanks to their unique mix of innovation-driven development, solid margins, and massive appreciation potential. Still, investors would do well to avoid businesses that feature some of the industry's bugbears like indebtedness, overly hig...
DexCom (NASDAQ:DXCM) said it secured CE Mark (Conformité Européenne) for the Dexcom G7 Continuous Glucose Monitoring system for people with diabetes in Europe age two years and older, including pregnant women. With Dexcom G7, real-time glucose readings are sent automatically to a co...
The best-selling real-time CGM in the world 1 is now more powerful and easier to use with a small, all-in-one wearable and completely redesigned mobile app New system has the fastest sensor warmup on the market,* with no fingersticks † or scanning required ...
DexCom (NASDAQ: DXCM) might just have significant untapped potential and even greater growth ahead. In this clip from "3 Minute Stocks Updates" on Motley Fool Live , recorded on Feb. 16 , Motley Fool contributors Brian Feroldi and Brian Withers discuss why DexCom investors a...
Lone Pine Capital’s 13F portfolio value decreased from $29.68B to $24.41B. The number of positions decreased from 39 to 29. They increased Amazon, RH, NetEase, Confluent, and Marqeta while reducing Block and dropping Moderna and Meta Platforms. The top three positions are A...
FHLC is a well-diversified healthcare ETF concentrated on large caps. FHLC generated strong return, and closely replicated returns of S&P 500. FHLC has strong price multiples and financial growth, at par with peers. For further details see: FHLC: Well Diversified, St...
News, Short Squeeze, Breakout and More Instantly...
2024-07-04 10:00:00 ET Growth-oriented investors have experienced a bit of a roller-coaster ride over the past few years. Many companies in the "growth stock" category were struggling just two years ago, but in the bull market we are now experiencing, they're delivering very different resul...
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, July 25, 2024. Management will hold a conference call to review the company's second quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the...